share_log

Is Now The Time To Look At Buying Laboratory Corporation of America Holdings (NYSE:LH)?

Is Now The Time To Look At Buying Laboratory Corporation of America Holdings (NYSE:LH)?

現在是考慮收購美國實驗室控股公司(紐約證券交易所代碼:LH)的時候了嗎?
Simply Wall St ·  03/11 07:05

Let's talk about the popular Laboratory Corporation of America Holdings (NYSE:LH). The company's shares maintained its current share price over the past couple of month on the NYSE, with a relatively tight range of US$215 to US$233. However, does this price actually reflect the true value of the large-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let's take a look at Laboratory Corporation of America Holdings's outlook and value based on the most recent financial data to see if there are any catalysts for a price change.

讓我們來談談廣受歡迎的美國實驗室控股公司(紐約證券交易所代碼:LH)。該公司的股票在過去幾個月中在紐約證券交易所維持了目前的股價,相對較窄的區間爲215美元至233美元。但是,這個價格真的反映了大盤股的真實價值嗎?還是它目前的估值被低估了,爲我們提供了買入的機會?讓我們根據最新的財務數據來看看美國實驗室控股公司的前景和價值,看看是否有任何價格變動的催化劑。

What's The Opportunity In Laboratory Corporation of America Holdings?

美國實驗室控股公司的機會是什麼?

Laboratory Corporation of America Holdings appears to be expensive according to our price multiple model, which makes a comparison between the company's price-to-earnings ratio and the industry average. We've used the price-to-earnings ratio in this instance because there's not enough visibility to forecast its cash flows. The stock's ratio of 48.24x is currently well-above the industry average of 24.22x, meaning that it is trading at a more expensive price relative to its peers. Another thing to keep in mind is that Laboratory Corporation of America Holdings's share price is quite stable relative to the rest of the market, as indicated by its low beta. This means that if you believe the current share price should move towards the levels of its industry peers over time, a low beta could suggest it is not likely to reach that level anytime soon, and once it's there, it may be hard for it to fall back down into an attractive buying range again.

根據我們的價格倍數模型,美國實驗室控股公司似乎很昂貴,該模型將該公司的市盈率與行業平均水平進行了比較。我們在這個例子中使用市盈率是因爲沒有足夠的可見性來預測其現金流。該股的48.24倍比率目前遠高於行業平均水平的24.22倍,這意味着與同行相比,其交易價格更昂貴。要記住的另一件事是,美國實驗室控股公司的股價與其他市場相比相當穩定,其低貝塔值就表明了這一點。這意味着,如果你認爲當前的股價會隨着時間的推移向同業的水平,那麼低的貝塔值可能表明它不太可能在短期內達到這個水平,一旦達到這個水平,可能很難再次回落到一個有吸引力的買入區間。

Can we expect growth from Laboratory Corporation of America Holdings?

我們能指望美國實驗室控股公司的增長嗎?

earnings-and-revenue-growth
NYSE:LH Earnings and Revenue Growth March 11th 2024
紐約證券交易所:LH 收益和收入增長 2024 年 3 月 11 日

Future outlook is an important aspect when you're looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it's the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. With profit expected to more than double over the next couple of years, the future seems bright for Laboratory Corporation of America Holdings. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation.

當你考慮買入股票時,未來前景是一個重要的方面,特別是如果你是尋求投資組合增長的投資者。儘管價值投資者會爭辯說,最重要的是相對於價格的內在價值,但更有說服力的投資論點是以低廉的價格獲得高增長潛力。預計未來幾年利潤將增加一倍以上,美國實驗室控股公司的前景似乎一片光明。看來該股的現金流即將增加,這應該會促進更高的股票估值。

What This Means For You

這對你意味着什麼

Are you a shareholder? LH's optimistic future growth appears to have been factored into the current share price, with shares trading above industry price multiples. At this current price, shareholders may be asking a different question – should I sell? If you believe LH should trade below its current price, selling high and buying it back up again when its price falls towards the industry PE ratio can be profitable. But before you make this decision, take a look at whether its fundamentals have changed.

你是股東嗎?LH樂觀的未來增長似乎已被納入當前股價的因素,股票的交易價格高於行業價格倍數。按照目前的價格,股東們可能會問另一個問題——我應該賣出嗎?如果您認爲LH的交易價格應低於其當前價格,那麼高價賣出並在其價格跌至行業市盈率時再次回購可能會有利可圖。但是在做出這個決定之前,先看看它的基本面是否發生了變化。

Are you a potential investor? If you've been keeping tabs on LH for some time, now may not be the best time to enter into the stock. The price has surpassed its industry peers, which means it is likely that there is no more upside from mispricing. However, the positive outlook is encouraging for LH, which means it's worth diving deeper into other factors in order to take advantage of the next price drop.

你是潛在的投資者嗎?如果你對LH的關注已經有一段時間了,那麼現在可能不是入股的最佳時機。該價格已經超過了業內同行,這意味着錯誤定價可能沒有更多的上行空間。但是,LH的樂觀前景令人鼓舞,這意味着值得深入研究其他因素,以利用下一次價格下跌的機會。

With this in mind, we wouldn't consider investing in a stock unless we had a thorough understanding of the risks. You'd be interested to know, that we found 4 warning signs for Laboratory Corporation of America Holdings and you'll want to know about these.

考慮到這一點,除非我們對風險有透徹的了解,否則我們不會考慮投資股票。你可能會有興趣知道,我們發現了美國實驗室控股公司的4個警告標誌,你會想知道這些信號的。

If you are no longer interested in Laboratory Corporation of America Holdings, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

如果您不再對美國實驗室公司控股感興趣,您可以使用我們的免費平台查看我們的其他50多隻具有高增長潛力的股票清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論